Clinical Trial
Study Details
Enrollment
33
Interventions
Description
Single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide.
Name
Hydroxycarbamide
Type
Drug
Phase
Phase 2
Status
COMPLETED
Study ID #
NCT05470270
Study Type
Interventional
Summary
This is a prospective, interventional, phase II, open-label, multicentre, national, non-comparative study of a single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide (Siklos® 100 mg and/or 1000 mg film-coated tablets).
Study Overview
Conditions
Contacts and Locations
Locations
Facility
InterCommunal Hospital Centre of Creteil
94000 Créteil
France
GeoPoint
48.79266, 2.46569
Facility
Necker University Hospital
75015 Paris
France
GeoPoint
48.85341, 2.3488
Facility
Robert Debré Hospital
75019 Paris
France
GeoPoint
48.85341, 2.3488